Pancreatic Cancer Research

ResearcherZhejiang Chinese Medical UniversityActive in the last 2 years

Nengming Lin

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-8392-3588; OpenAlex author ID A5103047116. Sources: OpenAlex.

Their work

Papers
5 (first author 0, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
8
Papers, trials and grants by year

2018: 1 paper · 2019: none · 2020: 3 papers · 2021: none · 2022: none · 2023: none · 2024: none · 2025: 1 paper

Papers 5

  1. AZD5153 enhances the chemo-sensitivity of gemcitabine on pancreatic cancer cells in vitro and in vivo. Co-author DOI 10.1186/s12935-025-03952-2↗
  2. The effect of ibrutinib on radiosensitivity in pancreatic cancer cells by targeting EGFR/AKT/mTOR signaling pathway. Last author DOI 10.1016/j.biopha.2020.110133↗
  3. Active ingredients of Inula helenium L. exhibits similar anti-cancer effects as isoalantolactone in pancreatic cancer cells. Last author DOI 10.1080/14786419.2018.1543676↗
  4. The Ibr-7 derivative of ibrutinib radiosensitizes pancreatic cancer cells by downregulating p-EGFR. Last author DOI 10.1186/s12935-020-01548-6↗
  5. Ethyl acetate extract from Inula helenium L. inhibits the proliferation of pancreatic cancer cells by regulating the STAT3/AKT pathway. Last author DOI 10.3892/mmr.2018.8534↗

Closest collaborators

The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Youyou Yan · 4 shared papers, 2018–2025 · strength 0.59
  2. Biqin Tan · 3 shared papers, 2020–2025 · strength 0.52
  3. Rong Dong · 2 shared papers, 2020–2025 · strength 0.36
  4. Lulin Zhu · 1 shared paper, 2025 · strength 0.23
  5. Bo Zhang · 1 shared paper, 2025 · strength 0.23
  6. Fei Wang · 1 shared paper, 2020 · strength 0.13
  7. Bo Zhang · 1 shared paper, 2020 · strength 0.13
  8. Bo Zhang · 1 shared paper, 2018 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.